Methods and Results
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- A new landscape for stroke prevention in atrial fibrillation: focus on new anticoagulants, antiarrhythmic drugs, and devices.Stroke. 2011; 42: 3316-3322
- Dabigatran versus warfarin in patients with atrial fibrillation.N Engl J Med. 2009; 361: 1139-1151
- The long-term multicenter observational study of dabigatran treatment in patients with atrial fibrillation (RELY-ABLE) study.Circulation. 2013; 128: 237-243
- Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial.Circulation. 2012; 125: 669-676
- Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients?.Am J Med. 2010; 123: 785-789
- Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials.Arch Intern Med. 2012; 172: 397-402
- Efficacy and safety of dabigatran etexilate and warfarin in “real-world” patients with atrial fibrillation: a prospective nationwide cohort study.J Am Coll Cardiol. 2013; 61: 2264-2273
- Evaluating medication effects outside of clinical trials: new-user designs.Am J Epidemiol. 2003; 158: 915-920
- Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study.BMJ Open. 2013; 3: e002758
- The Danish National Prescription Registry.Scand J Public Health. 2011; 39: 38-41
- The Danish National Patient Register.Scand J Public Health. 2011; 39: 30-33
- The Danish Civil Registration System.Scand J Public Health. 2011; 39: 22-25
- Observational data for comparative effectiveness research: an emulation of randomised trials of statins and primary prevention of coronary heart disease.Stat Methods Med Res. 2013; 22: 70-96
- Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease.Epidemiology. 2008; 19: 766-779
- An analytic framework for aligning observational and randomized trial data: application to postmenopausal hormone therapy and coronary heart disease.Stat Biosci. 2012; 5: 344-360
- Semiparametric regression for the mean and rate functions of recurrent events.J R Stat Soc Series B Stat Methodol. 2000; 62: 711-730
- Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation.Chest. 2010; 137: 263-272
- Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin.Circulation. 2004; 110: 2287-2292
- A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.Chest. 2010; 138: 1093-1100
- Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.Stat Med. 1999; 18: 695-706
- Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction?.J Thromb Thrombolysis. 2013; 35: 295-301
- Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation.Circulation. 2010; 122: 2246-2253
- Predictive values of acute coronary syndrome discharge diagnoses differed in the Danish National Patient Registry.J Clin Epidemiol. 2009; 62: 188-194
Funding: This study was funded by a grant from the Obel Family Foundation .
Conflict of Interest: GYHL has served as a consultant for Bayer, Astellas, Merck, Sanofi, BMS/Pfizer, Daiichi-Sankyo, Biotronik, Portola, and Boehringer Ingelheim, and has served as a speaker for Bayer, BMS/Pfizer, Boehringer Ingelheim, Daiichi-Sankyo, and Sanofi Aventis. TBL has received investigator-initiated educational grants from Bayer Healthcare and Boehringer Ingelheim, and served as a speaker for Boehringer Ingelheim, Bayer Healthcare, and BMS/Pfizer. In addition, DAL is on the Steering Committee of a Phase IV apixaban study (AEGEAN). Both GYHL and DAL have participated in various clinical trials of stroke prevention in atrial fibrillation. TBL has served as an investigator for Janssen Scientific Affairs, LLC and Boehringer Ingelheim. TBL and LHR have been on the speaker bureaus for Bayer, BMS/Pfizer, Janssen Pharmaceuticals, Takeda, Roche Diagnostics and Boehringer Ingelheim. The other authors have no conflicts of interest to declare. MR is a full-time employee of the Danish Health and Medicines Authority. The views expressed in this article reflect her personal views and do not necessarily represent the position of the Danish Health and Medicines Authority.
Authorship: TBL: original idea, wrote the first draft and made revisions; LHR, MR, DAL: interpreted data, edited and drafted revisions to the article; AGR, FS: analyzed the data, drafted and revised the paper; GYHL: co-wrote the first draft and made revisions. All authors had access to the data and a role in writing the manuscript.